This website is intended for UK healthcare professionals only. Not a UK healthcare professional? Click here.
Resources and support
Educational resources and expert opinions
Hear from experts discussing their opinions on the primary care management of hypercholesterolaemia/mixed dyslipidaemia.
Considerations for CVD risk reduction in patients with diabetes and elevated LDL-C
Join leading experts as they discuss key considerations for managing hypercholesterolaemia and mixed dyslipidaemia in patients with diabetes, with a focus on reducing their heightened CV risk through effective lipid-lowering therapies
Dr. Patrick Holmes and Beverley Bostock
8 mins
Lipid masterclass series -evidence into practice in CVD
In this video, experts discussed the unmet need in CV risk reduction and optimising lipid-lowering therapy. Learn about the challenges and opportunities in lipid management for your patients as well as insights from clinical studies which can be translated into your clinical practice
13 chapters
The eligible NILEMDO®/NUSTENDI® patient – who are they?
Discover which patients bempedoic acid (+/- ezetimibe) would be an appropriate therapeutic option for
6 mins
Optimising lipid management in type 2 diabetes and elevated LDL-C and real-world experience
In this video, Niraj Lakhani explored the management of dyslipidaemia in patients with type 2 diabetes, emphasised the importance of a partnership model to determine suitable treatment strategies and showcased how digital tools can enhance patient engagement and support
4 mins
Role of bempedoic acid in the management of CV risk reduction in type 2 diabetes and elevated LDL-C and real-world experience
In this video, Dr. Elnaggar emphasised the importance of lipid management in mitigating CV risk for patients with type 2 diabetes and elevated LDL-C. He highlighted the therapeutic potential of bempedoic acid as an LDL-C lowering agent in eligible patients living with type 2 diabetes
5 mins
Why should primary prevention lipid management be prioritised?
In this video, Laura Cox detailed why primary prevention lipid management should be a key focus for UK HCPs to reduce patients’ CVD risk, and emphasised the importance of identifying patient risk factors
3 mins
The role of bempedoic acid in the management of CV risk reduction in primary prevention lipid management
In this video, Nirali Sisodia highlighted the importance of CV risk reduction in primary prevention, advocating for a proactive strategy to support patients in reaching treatment LDL-C goals. She also explored the role of bempedoic acid, as an LDL-C lowering agent and the evidence supporting it’s use in patients at high-risk of a first CV event
3 mins
British Journal of Cardiology Advertorial
This advertorial explores the multifactorial challenges of managing CV risk and elevated cholesterol in primary care, outlining available treatment options, including NUSTENDI® (bempedoic acid + ezetimibe) and NILEMDO® (bempedoic acid). It reviews the clinical evidence and safety considerations for bempedoic acid, with the aim of supporting HCPs in implementing this information into their everyday clinical decision-making
10 mins
Practical resources and information
Patient resources that are only to be shared via HCPs and are not to be shown to patients from this website.
NUSTENDI® Patient Brochure
Downloadable brochure to support patients with their NUSTENDI® treatment
9 mins
NILEMDO® Patient Brochure
Downloadable brochure to support patients with their NILEMDO® treatment
7.30 mins
Access to implementation support and tools
This content is only for use by HCPs in the UK and other appropriate decision-making personnel* that support the management of patient care.
This content should not replace individual clinical judgement or processes that may already be in place. Clinical judgement should be applied when considering the applicability of this content.
*Other relevant decision makers particularly include those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply, or use of any medicine but who are not HCPs.
The logistics of implementing guidance and treatment pathways can be challenging. Daiichi Sankyo UK is pleased to offer personalised support, to help you ensure that eligible patients have access to NILEMDO® or NUSTENDI® when they need it.
Support available:
Formularies and Treatment Pathway Support
Contact the DSUK SBD Regional Access Managers for promotional support in shaping the healthcare ecosystem to enable access to lipid-lowering therapies. This support may include guidance on formulary inclusion, optimising treatment pathways and sharing best practice examples
Education for Pharmacy Professionals
Contact the DSUK SBD Regional Access Managers to arrange promotional educational support for pharmacy professionals in your locality about the clinical and practical implementation of lipid management with NILEMDO® and/or NUSTENDI®
Tools and materials available:
Lipid Implementation Pack
This toolkit offers valuable knowledge and practical strategies for the effective implementation of lipid management. This promotional resource is designed to support HCPs in incorporating lipid-lowering therapies, such as NILEMDO® and NUSTENDI® into clinical practice. Funded and developed by DSUK
Total System Value Pack
This model quantifies the burden of hypercholesterolaemia and mixed dyslipidaemia while demonstrating the holistic benefits of improved lipid management and goal attainment
Further Information
For information on Lipid Management Services offered by Daiichi Sankyo UK please see https://www.daiichi-sankyo.co.uk/about-us/responsibility/donations/ where you can submit a request for support or further information.
Abbreviations
CV, cardiovascular; CVD, cardiovascular disease; DSUK, Daiichi Sankyo UK; HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; NHS, National Health Service; SBD, speciality business division; UK, United Kingdom.
Job code: UK/BIL/01/26/0001|Date of preparation: June 2026